Nrx pharmaceuticals (nasdaq:nrxp) announces development of new, proprietary formulation of htx-100 (iv ketamine)

Formulation based on prior patents by nrx founder achieved ph neutral formulation of ketamine, potentially enabling both intravenous (iv) and subcutaneous (sq) administration company expects composition of matter patent protection company previously executed joint development agreement with us manufacturer of insulin pumps radnor, pa. , april 15, 2024 /prnewswire/ -- nrx pharmaceuticals, inc. (nasdaq: nrxp) ("nrx pharmaceuticals", "nrx", the "company"), a clinical-stage biopharmaceutical company, today announced that the company has developed a novel, proprietary formulation of iv ketamine for use as htx-100.
NRXP Ratings Summary
NRXP Quant Ranking